secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2025-05-30T23:59:59+00:00
Accession:  0001599298-25-000099
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit's ivonescimab meets PFS endpoint in global Phase III HARMONi; OS trend positive
--------------------------------------------------------------------------------

- Ivonescimab + chemo reduced risk of progression or death by 48% vs chemo alone (HR 0.52; p<0.00001).
- Overall survival showed positive trend (HR 0.79; p=0.057), not statistically significant.
- No new safety signals; Grade 3+ TEAEs 56.9% ivonescimab arm vs 50.0% control.
- Summit plans to file BLA with FDA but notes FDA requires statistically significant OS benefit.
- Consistent PFS benefit observed across Asia and ex-Asia (including North America) sub-populations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000099/0001599298-25-000099-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929825000099/smmt-20250530.htm
  HTML page:      https://secwatch.observer/filing/0001599298-25-000099

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer